Robust and reproducible peptide mapping and intact mass analysis workflows on a single instrument platform

Significance of the Topic

Peptide mapping and intact mass analysis are essential in biopharmaceutical development for confirming protein identity, verifying disulfide bond configurations, and quantifying post-translational modifications. Integrating these assays on a single LC–MS platform reduces workflow complexity, minimizes manual handling errors, and enhances reproducibility across laboratories.

Objectives and Study Overview

This work aims to demonstrate a unified analytical platform—Thermo Scientific™ Vanquish™ Flex UHPLC coupled to a Q Exactive™ HF Orbitrap mass spectrometer—for comprehensive characterization of recombinant somatotropin. The proposed workflow combines rapid digestion, peptide mapping, and intact protein mass analysis in a streamlined manner.

Applied Methodology and Instrumentation

The protein sample was digested using immobilized, heat-stable trypsin (SMART Digest™ kit) at 70 °C for 5–15 minutes, followed by reduction for disulfide bond analysis. Peptide separations employed a reversed-phase C18 column with a 30-minute gradient. Intact mass measurements under denaturing and native conditions were performed by swapping to RP and SEC columns without changing eluents. Data processing and sequence confirmation utilized BioPharma Finder™ software.

Used Instrumentation

• Vanquish Flex Quaternary UHPLC system with SmartSampler and Diode Array Detector
• Thermo Scientific™ Q Exactive™ HF Hybrid Quadrupole-Orbitrap™ MS with BioPharma option
• Acclaim™ VANQUISH™ C18 column, MAbPac™ RP column, and Acclaim™ SEC-300 column
• SMART Digest™ kit and KingFisher™ purification for sample preparation

Main Results and Discussion

Peptide mapping achieved 100% sequence coverage, including identification of all expected tryptic peptides and native disulfide-linked peptides. Reduction released four individual cysteine-containing peptides previously observed as two disulfide-linked species. Quantification of low-level modifications (deamidation, oxidation, isomerization) was obtained at <2% abundance. Intact mass analysis yielded monoisotopic masses within 1.5 ppm of theoretical under both denaturing (22 111.0920 Da) and native (22 111.0754 Da) conditions, demonstrating isotopic resolution and high mass accuracy.

Benefits and Practical Applications of the Method

• Single-platform operation for peptide mapping and intact protein confirmation
• Rapid, one-hour end-to-end workflow with minimal user intervention
• Fully automated data acquisition and processing using Chromeleon CDS and BioPharma Finder
• Enhanced confidence in critical quality attribute assessment for QC environments

Future Trends and Opportunities

Further automation of digestion and column switching can support high-throughput labs. Expanding native MS assays to higher-order structure characterization, coupling online fractionation, and machine-learning–driven data interpretation will drive next-generation multi-attribute methods for biotherapeutic development.

Conclusion

Integrating peptide mapping and intact mass analysis on a single UHPLC–Orbitrap system yields robust, reproducible assays for comprehensive protein characterization. The SMART Digest workflow and BioPharma Finder software enabled complete sequence verification, disulfide bond mapping, and low-level modification quantification within a rapid one-hour protocol.

References

1. Rogers RS et al. Development of a quantitative mass spectrometry multiattribute method for characterization, quality control testing and disposition of biologics. mAbs. 2015;7(5):881–890.
2. Ren D et al. An improved trypsin digestion method minimizes digestion-induced modifications on proteins. Anal Biochem. 2009;392:12–21.
3. Kollipara L, Zahedi RP. Protein carbamylation: in vivo modification or in vitro artefact? Proteomics. 2013;13:941–944.
4. Samonig M et al. SMART Digest compared to classic in-solution digestion of rituximab for in-depth peptide mapping characterization. Thermo Fisher Sci App Note. 2016;1159.
5. Schwahn A et al. LC/MS analysis of the monoclonal antibody rituximab using the Q Exactive benchtop Orbitrap mass spectrometer. Thermo Fisher Sci App Note. 2013;591.